Use of xanthine in the preparation of a medicament for repairing damage to respiratory epithelium

Abstract

The application belongs to the technical field of biological medicine, and discloses application of xanthine in repairing respiratory epithelial injury drugs and a chronic obstructive pulmonary disease (COPD) organoid model construction and evaluation method. In view of the defects that existing treatment focuses on inflammation control, relies on multi-drug combination, lacks epithelial repair targeting and has low pathological similarity in vitro model, an airway-alveolus organoid model is innovatively constructed, the pathological chain of COPD airway injury-alveolus destruction can be completely reproduced, and a multi-dimensional evaluation system is established. Based on the model, it is first proved that xanthine single drug can significantly promote proliferation of damaged airway organoid cells, inhibit abnormal apoptosis, selectively down-regulate release of inflammatory factors such as TNF-alpha and CXCL1, promote alveolus organoid AT2 cell proliferation and regeneration, and repair alveolus homeostasis at a concentration of 20-100 muM without combination with other drugs. Xanthine is an endogenous purine metabolite, is safe and low-toxic, solves the pain points of existing drug combination dependence and side effects, and realizes upgrading from inflammation control to structure repair. Xanthine can be made into oral or respiratory tract local preparations, is suitable for repairing epithelial injury of respiratory diseases such as COPD and asthma, is suitable for a wide range of people, has significant clinical and industrialization values, and the innovative model also provides a reliable tool for related drug research and development.

Images